A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Psoriasis Treated With Ustekinumab and Other Types of Biological and Systemic Non-biological Treatments.
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Ustekinumab (Primary) ; Antipsoriatics; Tumour necrosis factor inhibitors
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Janssen Biotech
- 14 Jun 2018 Status changed from active, no longer recruiting to completed.
- 10 Feb 2017 Planned number of patients changed from 1000 to 2000.
- 23 Apr 2012 Actual initiation date (Aug 2009) added as reported by ClinicalTrials.gov.